Search clinical trials for: Placebo of SPM 962

Total 28742 results

Otsuka Pharmaceutical Co., Ltd.

Completed

Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)

Idiopathic Restless Legs Syndrome

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

Early Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
UCB Pharma

Completed

A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease

Parkinson's Disease

Germany
UCB Pharma

Completed

Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa

Parkinson Disease, Idiopathic

Germany
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome (RLS)

Idiopathic Restless Legs Syndrome
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients

Idiopathic Restless Legs Syndrome

Japan
University of California, San Francisco

Completed

THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

Vascular Diseases | Osteoarthritis | Peripheral Arterial Disease | Claudication | Vascular Calcification | Claudication, Intermittent | Vascular Occlusion

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Sparrow Pharmaceuticals

Active, not recruiting

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome (RESCUE)

Cortisol; Hypersecretion | Cortisol Overproduction | Cushing's Syndrome I | Cushing Disease Due to Increased ACTH Secretion | Cortisol Excess | Ectopic ACTH Secretion

United States, Bulgaria, Romania
UCB Pharma

Completed

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms

Parkinson's Disease
Bayer

Completed

To Evaluate Eye Installation-Tear Free

Sunscreening Agents

United States
UCB Pharma
SCHWARZ BIOSCIENCES GmbH - Part of UCB Group

Completed

A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy

Painful Diabetic Neuropathy

Germany
AbbVie

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

Healthy Volunteers | Generalized Anxiety Disorder (GAD) | Bipolar Disorder (BPD)

United States
NeurAxon Inc.

Completed

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Post Herpetic Neuralgia

United States, Canada
Cortria Corporation

Completed

A Study to Evaluate the Lipid Regulating Effects of TRIA-662

Hyperlipidemia
Pfizer

Completed

Multiple Ascending Dose Study To Assess Safety, Tolerability And Pharmacokinetics Of PF-05212377 (SAM-760) (MAD)

Healthy

France
Vanda Pharmaceuticals

Completed

VEC-162 Study in Adult Patients With Primary Insomnia

Primary Insomnia

United States
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes Type 2

Japan
Novartis Pharmaceuticals

Terminated

Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants

Healthy Volunteers

United Kingdom
Neuronascent, Inc.
National Institute on Aging (NIA)

Completed

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

Alzheimer Disease

United States
Concert Pharmaceuticals

Completed

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

Healthy

United States
UCB Pharma

Completed

A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927

Epilepsy
Expansion Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

Myotonic Dystrophy | Myotonic Dystrophy, Type 1 (DM1)

United States
Cortria Corporation
Montreal Heart Institute

Completed

A Pilot Study to Evaluate the Lipid Effects of TRIA-662

Hypertriglyceridemia | Mixed Hyperlipidemia

Canada
GlaxoSmithKline

Completed

Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy

Muscular Dystrophies

Germany, Belgium, Turkey, Netherlands, Spain, Israel, Australia, France, United Kingdom
Vanda Pharmaceuticals

Completed

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Insomnia

United States
Second Genome

Terminated

Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer Disease

United States
Supernus Pharmaceuticals, Inc.

Terminated

Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

Attention Deficit Hyperactivity Disorder

United States
SCM Lifescience Co., LTD.

Completed

Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

Korea, Republic of
SCM Lifescience Co., LTD.

Completed

Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis

Pancreatitis, Acute

Korea, Republic of
Supernus Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

Impulsive Aggression Comorbid With ADHD

United States
AbbVie
Gedeon Richter Plc.

Recruiting

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

Healthy Participants | Generalized Anxiety Disorder (GAD)

United States
Elgan Pharma Ltd.

Terminated

Safety and Efficacy Study in Infant With SBS (GIFT)

Short Bowel Syndrome

United States
FORUM Pharmaceuticals Inc
Parexel

Completed

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Mild Cognitive Impairment | Alzheimer's Disease

United States
Vanda Pharmaceuticals

Completed

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States, Germany
Supernus Pharmaceuticals, Inc.

Recruiting

Therapy for Migraine Prevention in Children 6-11 Years of Age

Migraine Disorders | Headache Disorders

United States
SCM Lifescience Co., LTD.

Active, not recruiting

Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease

Chronic Graft-versus-host-disease

Korea, Republic of
Sunovion
PPD; ICON Clinical Research; Covance; Dainippon Sumitomo Pharma America; ClinPhone...

Completed

SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)

Overactive Bladder Syndrome (OABS)

France, United Kingdom, United States, Estonia, Germany, Latvia, Lithuania, Poland, Spain
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531

Alzheimer Disease

France
CrystalGenomics, Inc.

Completed

Multiple Ascending Doses Study of CG400549

Healthy

Netherlands
Infinity Pharmaceuticals, Inc.

Completed

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Conventional Chondrosarcoma

United States, Italy, Canada, Austria, Australia, Germany, France, Netherlands, Norway, Poland, Russian Federation, Sweden, United Kingdom
Supernus Pharmaceuticals, Inc.

Withdrawn

Classroom Study of SPN-812 in Children With ADHD

ADHD
Supernus Pharmaceuticals, Inc.

Completed

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

ADHD

United States
Supernus Pharmaceuticals, Inc.

Completed

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

ADHD

United States

3

Subscribe